<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399253</url>
  </required_header>
  <id_info>
    <org_study_id>GCGC004</org_study_id>
    <nct_id>NCT03399253</nct_id>
  </id_info>
  <brief_title>Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor</brief_title>
  <official_title>A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial of Chemotherapy Alone Versus D2 Gastrectomy and Metastasectomy Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims to compare the efficacy and safety of Chemotherapy Alone Versus D2 distal
      gastrectomy and metastasectomy plus Chemotherapy for gastric cancer (GC) with one non-curable
      Factor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is the fourth most common malignancy worldwide and the second leading cause of
      cancer-related deaths, with the highest mortality rates reported in East Asia, including
      China. Many patients are diagnosed at an advanced stage of gastric cancer because of late
      onset and nonspecific symptoms. The prognosis of patients with advanced gastric cancer with
      non-curable factors, such as hepatic, peritoneal, or distant lymph node metastases, is poor.
      Chemotherapy is the standard of care for these patients. Palliative resection or bypass
      surgery is generally indicated in the presence of major symptoms such as bleeding or
      obstruction for incurable advanced gastric cancer. The usefulness of gastrectomy and
      metastasectomy is still unclear.

      The REGATTA trial is the first clinical trial to explore the significance of surgery for
      incurable advanced gastric cancer. However, it concluded an opposite conclusion that
      gastrectomy followed by chemotherapy did not show any survival benefit compared with
      chemotherapy alone in advanced gastric cancer with a single non-curable factor.
      Interestingly, there was a significant interaction between treatment effect and tumor
      location in subgroup analyses of overall survival. Gastrectomy plus chemotherapy was
      associated with significantly worse overall survival in patients with upper-third tumors for
      less chemotherapy cycles. This finding raises the question whether inclusion criteria were
      restricted to the patients with lower-third tumor, findings of study might have been
      positive. So we raise this new trail to assess the significance of Gastrectomy and
      Metastasectomy for Distal Gastric Cancer With One Non-curable Factor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-year</time_frame>
    <description>OS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3-year</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery+Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>D2 gastrectomy + metastasectomy</description>
    <arm_group_label>Surgery+Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Surgery+Chemotherapy</arm_group_label>
    <other_name>XELOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old.

          2. PS (ECOG) of 0 or 1.

          3. Without any other malignancies.

          4. Written informed consent from the patient.

          5. Standard gastrectomy with D2 lymphadenectomy for primary cancer

          6. A single non-curable factor was defined by preoperative CT :

             hepatic metastasis (H1 or H2; maximum diameter ≤4 cm, number ≤4); peritoneal
             metastasis (R0 or R1 resection) para-aortic lymph node metastasis （number ≤4) ovarian
             metastasis adrenal metastasis renal metastasis

          7. No contraindications to chemotherapy, including normal peripheral blood routine, liver
             and kidney function and electrocardiogram （WBC≥4.0 x 109 /L, NEU≥1.5 x 109 /L,PLT≥100
             x 109 /L and HGB≥90g/L)

        Exclusion Criteria:

          1. Female in pregnancy or lactation.

          2. Supraclavicular lymph nodes metastases，lung and bone metastases.

          3. Massive ascites or cachexia.

          4. Extensive cancer metastases of liver, peritoneal metastasis,para-aortic lymph node

          5. Patients participating in any other clinical trails currently，or participated in other
             trails within 1 months.

          6. Suffering from other serious diseases, including cardiovascular, respiratory, kidney,
             or liver disease, complicated by poorly controlled hypertension, diabetes, mental
             disorders or diseases.

          7. Poor treatment compliance of patients

          8. The group of chemotherapy alone accepts gastrectomy for bleeding or obstruction

          9. Failure of R0 or R1 metastasectomy and gastrectomy with D2 lymphadenectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dazhi Xu, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dazhi Xu, PHD</last_name>
    <phone>(+86) 020-87343737</phone>
    <email>xudzh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anqing Municipal Hospital</name>
      <address>
        <city>Anqing</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaming Zhang</last_name>
    </contact>
    <contact_backup>
      <last_name>Daibin Tang</last_name>
      <phone>13865176528</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuhui Zhao</last_name>
      <phone>18963789289</phone>
    </contact>
    <contact_backup>
      <last_name>Yifu He</last_name>
      <phone>13485691976</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aman Xu</last_name>
      <phone>13705695470</phone>
    </contact>
    <contact_backup>
      <last_name>Fei Zhong</last_name>
      <phone>18226616729</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianghui Shi</last_name>
      <phone>13956159006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dazhi Xu</last_name>
      <phone>86(020)87343737</phone>
      <email>xudzh@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Youqing Zhan</last_name>
      <phone>86(020)87343910</phone>
      <email>Zhanyq@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Yuebei People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Tao Zhang</last_name>
      <phone>13500206389</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huamin Rao</last_name>
      <phone>13879100685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Chen</last_name>
      <phone>13958092350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupeng Zhang</last_name>
      <phone>13920561244</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dazhi Xu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Distal Gastric Cancer, Gastrectomy, Metastasectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

